Orexo strengthens IP rights for overdose rescue drug OX124
· Patent protection until 2039 · Previous human pharmacokinetic (PK) study showed significantly better PK profile when compared to market leading product Uppsala, Sweden – January 27, 2021 – Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY) today announces that the company has further strengthened the intellectual property (IP) for its flagship pharmaceutical pipeline asset OX124, a naloxone rescue medication for the treatment of opioid overdose. The US Patent and Trademark Office (USPTO) has issued a new patent protecting the product until 2039. The new patent, US 10,898,480, is the